Veradermics Completes Enrollment in Two Phase 3 Trials for Male Pattern Hair Loss Treatment

Event summary

  • Veradermics completed enrollment in its second Phase 3 trial for VDPHL01, an oral extended-release minoxidil treatment for male pattern hair loss.
  • The trial enrolled 536 male participants with mild-to-moderate pattern hair loss, bringing the total enrollment across both Phase 3 trials to over 1,000 participants.
  • VDPHL01 is designed to maximize hair restoration while minimizing cardiac side effects through its extended-release formulation.
  • Topline data from the first Phase 2/3 trial is anticipated in the first half of 2026.
  • Veradermics is also recruiting participants for a Phase 2/3 trial in females with pattern hair loss.

The big picture

Veradermics' completion of enrollment in two Phase 3 trials for VDPHL01 represents a significant step forward in the development of an oral treatment for male pattern hair loss. The company's extended-release formulation of minoxidil aims to address the limitations of current treatments, which have seen little innovation in decades. With the potential to be the first FDA-approved oral non-hormonal treatment for pattern hair loss, VDPHL01 could capture a substantial share of the growing aesthetics market.

What we're watching

Regulatory Pathway
Whether Veradermics can successfully file a new drug application for VDPHL01 and secure FDA approval, marking the first oral non-hormonal treatment for pattern hair loss in nearly 30 years.
Clinical Efficacy
The pace at which topline data from the Phase 2/3 trial will be released and whether it confirms the preliminary visible and measurable hair growth observed in earlier trials.
Market Potential
How the completion of these trials positions Veradermics in the $30 billion aesthetics market, projected to grow by 2028, and the potential for VDPHL01 to address the unmet needs of 80 million pattern hair loss sufferers in the U.S.